{"nctId":"NCT00690573","briefTitle":"Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis","startDateStruct":{"date":"2008-05"},"conditions":["Juvenile Rheumatoid Arthritis"],"count":25,"armGroups":[{"label":"Adalimumab","type":"EXPERIMENTAL","interventionNames":["Biological: Adalimumab"]}],"interventions":[{"name":"Adalimumab","otherNames":["adalimumab, ABT-D2E7, Humira"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Diagnosis of polyarticular juvenile rheumatoid arthritis (JRA) according to the criteria of the American College on Rheumatology (ACR)\n* Disease activity inadequately controlled by nonsteroidal anti-inflammatory drugs (NSAIDs) or methotrexate (MTX)\n* Presence at screening of at least 5 swollen joints (not due to deformity) and at least 3 joints with limitation of passive motion with pain by passive motion or/and pain by pressure (tenderness)\n* Stable dosage of MTX for at least 12 weeks prior to the screening visit or discontinuation of MTX at least 14 days prior to baseline visit (Day 1)\n* Discontinuation of disease-modifying antirheumatic drugs (DMARDs) other than MTX at least 28 days before screening visit\n\nExclusion Criteria\n\n* History of inflammatory joint disease other than JRA\n* Functional class IV JRA by ACR criteria\n* Clinically significant cardiac disease or laboratory abnormalities\n* Any subject who is considered by the investigator, for any reason, to be an unsuitable candidate for the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16","description":"Response defined as at least 30% improvement in 3 or more of 6 juvenile rheumatoid arthritis (JRA) core set criteria, and at least 30% worsening in not more than 1 JRA criterion, compared with baseline. JRA core set criteria include physician's global assessment of disease severity; parent's/patient's global assessment of overall well-being; number of active joints (joints with swelling or with limitation of motion \\[LOM\\] and with pain, tenderness or both); number of joints with LOM; physical function of the Disability Index of Childhood Health Assessment Questionnaire; C-reactive protein.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving PedACR50 and PedACR70 Responses at Week 16","description":"Response defined as at least 50/70% improvement in 3 or more of 6 juvenile rheumatoid arthritis (JRA) core set criteria, and at least 50/70% worsening in not more than 1 JRA criterion compared with baseline. JRA core set criteria include physician's global assessment of disease severity; parent's/patient's global assessment of overall well-being; number of active joints (joints with swelling or with limitation of motion \\[LOM\\] and with pain, tenderness or both); number of joints with LOM; physical function of the Disability Index of Childhood Health Assessment Questionnaire; C-reactive protein.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving PedACR 30/50/70 Responses","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Serum Adalimumab Concentration","description":"Blood samples were drawn prior to drug administration. Adalimumab concentrations in serum were determined using a validated enzyme-linked immunosorbent assay (ELISA) method based on a double-antigen technique. Concentrations are reported as micrograms per milliliter (mcg/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.24","spread":"1.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.46","spread":"5.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.15","spread":"5.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.73","spread":"5.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.79","spread":"6.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.60","spread":"7.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.97","spread":"6.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":"9.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.03","spread":"1.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.63","spread":"2.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.66","spread":"4.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"6.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"6.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":"6.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":"8.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"6.73"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Positive for Anti-adalimumab Antibodies (AAA)","description":"Serum samples with adalimumab concentration below 2 mcg/mL were selected for AAA analyses. Samples were considered AAA positive if the measured AAA concentration was above 20 ng/mL. A subject was considered to be AAA positive if the subject had at least one AAA positive sample observed within 30 days following the subject's last adalimumab dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":25},"commonTop":["nasopharyngitis","upper respiratory tract infection","influenza","pharyngitis","gastroenteritis"]}}}